Besides Soberana 02, Cuba has developed four COVID-19 vaccines: Soberana 01 and Soberana Plus, which were also created by FVI, and Abdala and Mambisa, which were developed by the Center for Genetic Engineering and Biotechnology (CIGB).
All Cuban vaccines contain "a protein subunit" so they produce an immune response through the inoculation of a COVID-19 spike protein. In the IFV vaccines, the antigen was grown in mammalian cells. With the CIGB products, on the other hand, the spike protein was cultivated in yeasts.
Cuba’s Center for the Control of Medicines, Equipment and Medical Devices is currently evaluating Abdala prototype to get the official vaccine status. Health authorities' purpose is to have 70 percent of the population vaccinated in September and 100 percent before the end of the year.
The COVID-19 vaccines created by #Cuba, Soberana 02 and Abdala, are the first two created in Latin America, and have an efficacy of 62% and 92.28%, respectively. pic.twitter.com/j4eFQYtKpP